NCT07302971 Telemedicine-supported Management for Acute Ischemic Stroke
| NCT ID | NCT07302971 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Capital Medical University |
| Condition | Acute Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,400 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,400 participants in total. It began in 2026-02-02 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Telemedicine-supported stroke care can provide standardized guidance to hospitals and regions with limited medical resources, thereby improving treatment outcomes for stroke patients in these areas. While this approach has been widely adopted in many developed countries, its efficacy in guiding basic-level hospitals to manage acute ischemic stroke requires further investigation through large-scale, high-quality studies. This study focused on patients with acute ischemic stroke who sought treatment at basic-level hospitals, aiming to investigate the efficacy and safety of treating acute ischemic stroke with telemedicine-supported management. Hospitals assigned to the experimental group received remote consultation guidance, quality control and professional training from expert teams at leading stroke centers, China National Center for Neurological Disorders. Hospitals in the control group did not receive telemedicine-supported management.
Eligibility Criteria
Inclusion Criteria: * Hospital Inclusion Criteria: 1. Basic-level hospitals in China (Definition: Hospitals classified as secondary-level (Grade II) or below under China's Hospital Grading Management Standards, or hospitals located in counties/county-level cities). 2. Equipped with an emergency department and neurology ward capable of admitting stroke patients. 3. Equipped with CT and/or MRI capable of diagnosing AIS. 4. Equipped with intravenous thrombolytic drugs for acute ischemic stroke. * Patient Inclusion Criteria: 1. Age ≥ 18 years. 2. Diagnosed with acute ischemic stroke. 3. CT/MRI confirms absence of intracerebral hemorrhage. 4. Onset of stroke symptoms ≤ 4.5 hours. 5. pre-stroke mRS score ≤1. 6. Informed consent obtained from patient or their legal representative. Exclusion Criteria: * Hospital Exclusion Criteria: 1. Admitting fewer than 10 patients with acute ischemic stroke per month. 2. Currently participating in other clinical trials that may interfere with this trial. * Patient Exclusion Criteria: 1. Presence of contraindications for intravenous thrombolysis according to AHA/ASA guidelines
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07302971 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07302971 currently recruiting?
Yes, NCT07302971 is actively recruiting participants. Contact the research team at jixm@ccmu.edu.cn for enrollment information.
Where is the NCT07302971 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07302971 clinical trial?
NCT07302971 is sponsored by Capital Medical University. The trial plans to enroll 2,400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.